IMMU Immunomedics Inc.

33.59
+0.29  (+1%)
Previous Close 33.3
Open 33.8
Price To Book 41.47
Market Cap 7,755,933,385
Shares 230,900,071
Volume 3,375,278
Short Ratio
Av. Daily Volume 5,678,126
Stock charts supplied by TradingView

NewsSee all news

  1. Immunomedics to Participate in Upcoming Healthcare Conferences

    MORRIS PLAINS, N.J., May 28, 2020 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (NASDAQ:IMMU) ("Immunomedics" or the "Company"), a leading biopharmaceutical company in the area of antibody-drug conjugates, today announced

  2. Immunomedics Announces Leadership Change and Provides Business Update Amid COVID-19

    MORRIS PLAINS, N.J., May 27, 2020 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (NASDAQ:IMMU) ("Immunomedics" or the "Company"), a leading biopharmaceutical company in the area of antibody-drug conjugates, today provided a

  3. Immunomedics to Present New Trodelvy™ Data In Non-Breast Cancer Indications at the 2020 ASCO Virtual Meeting

    MORRIS PLAINS, N.J., May 13, 2020 (GLOBE NEWSWIRE) -- Immunomedics, Inc., (NASDAQ:IMMU) ("Immunomedics" or the "Company"), a leading biopharmaceutical company in the area of antibody-drug conjugates (ADC), today

  4. Immunomedics to Participate in BofA Securities 2020 Health Care Conference

    MORRIS PLAINS, N.J., May 07, 2020 (GLOBE NEWSWIRE) -- Immunomedics, Inc., (NASDAQ:IMMU) ("Immunomedics" or the "Company"), a leading biopharmaceutical company in the area of antibody-drug conjugates, today announced

  5. Immunomedics Reports First Quarter 2020 Results and Provides Corporate Update

    Trodelvy™ received accelerated approval from FDA for third-line metastatic triple-negative breast cancer First patient treated with Trodelvy following successful commercial launch ASCENT study stopped early due to

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 1/2 data February 11, 2019 noted ORR 31% (14/45), with 2 CRs and 12 PRs. Presentation ASCO-GU February 15, 2019.
SACITUZUMAB GOVITECAN
Urothelial cancer
FDA Approval announced April 22, 2020.
SACTUZUMAB GOVITECAN (IMMU-132)
Triple-negative breast cancer
Phase 3 trial terminated due to poor efficacy
Clivatuzumab tetraxetan
Cancer - Pancreatic
Endpoints not met July 2015
Epratuzumab (EMBODY 1 and 2)
Lupus
Phase 3 enrolment to resumed mid-May 2020.
SACTUZUMAB GOVITECAN (IMMU-132) - TROPICS-02
HR+/HER2- metastatic breast cancer
Phase 1/2 top-line data due 2H 2020.
SACITUZUMAB GOVITECAN - TROPHY U-01
Urothelial cancer
Phase 1/2 trial update due fall of 2020.
Lucitanib with Rubraca (SEASTAR)
Ovarian cancer
Phase 2 preliminary results to be evaluated in 2020.
SACTUZUMAB GOVITECAN (IMMU-132) - TROPICS-03
Solid tumors
Phase 3 trial stopped due to compelling efficacy. Data due mid-2020.
SACTUZUMAB GOVITECAN (IMMU-132) - ASCENT
Cancer - metastatic triple-negative breast cancer

Latest News

  1. Immunomedics to Participate in Upcoming Healthcare Conferences

    MORRIS PLAINS, N.J., May 28, 2020 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (NASDAQ:IMMU) ("Immunomedics" or the "Company"), a leading biopharmaceutical company in the area of antibody-drug conjugates, today announced

  2. Immunomedics Announces Leadership Change and Provides Business Update Amid COVID-19

    MORRIS PLAINS, N.J., May 27, 2020 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (NASDAQ:IMMU) ("Immunomedics" or the "Company"), a leading biopharmaceutical company in the area of antibody-drug conjugates, today provided a

  3. Immunomedics to Present New Trodelvy™ Data In Non-Breast Cancer Indications at the 2020 ASCO Virtual Meeting

    MORRIS PLAINS, N.J., May 13, 2020 (GLOBE NEWSWIRE) -- Immunomedics, Inc., (NASDAQ:IMMU) ("Immunomedics" or the "Company"), a leading biopharmaceutical company in the area of antibody-drug conjugates (ADC), today

  4. Immunomedics to Participate in BofA Securities 2020 Health Care Conference

    MORRIS PLAINS, N.J., May 07, 2020 (GLOBE NEWSWIRE) -- Immunomedics, Inc., (NASDAQ:IMMU) ("Immunomedics" or the "Company"), a leading biopharmaceutical company in the area of antibody-drug conjugates, today announced

  5. Immunomedics Reports First Quarter 2020 Results and Provides Corporate Update

    Trodelvy™ received accelerated approval from FDA for third-line metastatic triple-negative breast cancer First patient treated with Trodelvy following successful commercial launch ASCENT study stopped early due to

  6. Immunomedics Announces Commercial Availability of TRODELVY™ in the United States

    MORRIS PLAINS, N.J., May 04, 2020 (GLOBE NEWSWIRE) -- Immunomedics, Inc., (NASDAQ:IMMU) ("Immunomedics" or the "Company"), a leading biopharmaceutical company in the area of antibody-drug conjugates (ADC), today

  7. Immunomedics Announces Closing Of Public Offering Of Common Stock

    MORRIS PLAINS, N.J., May 01, 2020 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (NASDAQ:IMMU) ("Immunomedics" or the "Company"), a leading biopharmaceutical company in the area of antibody-drug conjugates, today announced the

  8. Immunomedics to Report First Quarter 2020 Results and Host Conference Call and Webcast On May 6, 2020

    MORRIS PLAINS, N.J., April 30, 2020 (GLOBE NEWSWIRE) -- Immunomedics, Inc., (NASDAQ:IMMU) ("Immunomedics" or the "Company"), a leading biopharmaceutical company in the area of antibody-drug conjugates, today announced

  9. Immunomedics Announces Pricing of Public Offering of Common Stock

    MORRIS PLAINS, N.J., April 28, 2020 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (NASDAQ:IMMU) ("Immunomedics" or the "Company"), a leading biopharmaceutical company in the area of antibody-drug conjugates, today announced

  10. Immunomedics Announces Proposed Public Offering Of Common Stock

    MORRIS PLAINS, N.J., April 27, 2020 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (NASDAQ:IMMU) ("Immunomedics" or the "Company"), a leading biopharmaceutical company in the area of antibody-drug conjugates, today announced

  11. Everest Medicines Announces That Licensing Partner Immunomedics has Received FDA Accelerated Approval for Trodelvy (sacituzumab govitecan-hziy) in Previously-treated Metastatic Triple-Negative Breast Cancer

    SHANGHAI, China, April 24, 2020 (GLOBE NEWSWIRE) -- Everest Medicines, a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products that address critical unmet medical

  12. FDA Grants Accelerated Approval for Immunomedics' Trodelvy in Previously-Treated Metastatic Triple-Negative Breast Cancer

    First FDA-approved antibody-drug conjugate that targets the Trop-2 antigen Trodelvy is the first antibody-drug conjugate approved by FDA specifically for the treatment of relapsed or refractory metastatic

  13. CORRECTION - FDA GRANTS FAST TRACK DESIGNATION TO SACITUZUMAB GOVITECAN FOR LOCALLY-ADVANCED OR METASTATIC UROTHELIAL CANCER

  14. FDA GRANTS FAST TRACK DESIGNATION TO SACITUZUMAB GOVITECAN FOR NEOADJUVANT/ADJUVANT METASTATIC UROTHELIAL CANCER

  15. IMMUNOMEDICS ANNOUNCES ASCENT STUDY TO BE STOPPED FOR COMPELLING EFFICACY

    Decision based on recommendation from DSMC following study data review Sacituzumab govitecan has the potential to be the first FDA-approved antibody-drug conjugate for the treatment of metastatic triple-negative breast

  16. IMMUNOMEDICS TO HOST CONFERENCE CALL AND WEBCAST ON APRIL 6, 2020 TO PROVIDE CLINICAL AND CORPORATE UPDATE

    MORRIS PLAINS, N.J., April 03, 2020 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (NASDAQ:IMMU) ("Immunomedics" or the "Company"), a leading biopharmaceutical company in the area of antibody-drug conjugates, today announced

  17. IMMUNOMEDICS PROVIDES COVID-19 BUSINESS CONTINUITY UPDATE, AFFIRMS 2020 STRATEGIC PRIORITIES, AND SHARES R&D AND REGULATORY UPDATE

    MORRIS PLAINS, N.J., March 25, 2020 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (NASDAQ:IMMU) ("Immunomedics" or the "Company"), a leading biopharmaceutical company in the area of antibody-drug conjugates, today provided a

  18. Immunomedics Appoints Robert W. Azelby to Board of Directors

    MORRIS PLAINS, N.J., Feb. 27, 2020 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (NASDAQ:IMMU) ("Immunomedics" or the "Company"), a leading biopharmaceutical company in the area of antibody-drug conjugates (ADCs), today

  19. Immunomedics Reports Fourth Quarter and Full Year 2019 Results and Provides Corporate Update

    BLA resubmitted and accepted for filing by FDA, with a June 2, 2020 PDUFA date TROPHY U-01 expanded to combine sacituzumab govitecan with Keytruda® in I/O naïve patients New investigator-initiated study launched to

  20. Immunomedics to Participate in Upcoming Healthcare Conferences

    MORRIS PLAINS, N.J., Feb. 25, 2020 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (NASDAQ:IMMU) ("Immunomedics" or the "Company"), a leading biopharmaceutical company in the area of antibody-drug conjugates, today announced

  21. Immunomedics to Report Results for the Fourth Quarter and Full Year 2019 and Host Conference Call and Webcast on February 27, 2020

    MORRIS PLAINS, N.J., Feb. 20, 2020 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (NASDAQ:IMMU) ("Immunomedics" or the "Company"), a leading biopharmaceutical company in the area of antibody-drug conjugates, today announced

  22. Immunomedics Appoints Dr. Loretta Itri Chief Medical Officer

    MORRIS PLAINS, N.J., Feb. 14, 2020 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (NASDAQ:IMMU) ("Immunomedics" or the "Company"), a leading biopharmaceutical company in the area of antibody-drug conjugates, today announced

  23. Immunomedics to Participate in Guggenheim Healthcare Talks | Oncology Day

    MORRIS PLAINS, N.J., Feb. 06, 2020 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (NASDAQ:IMMU) ("Immunomedics" or the "Company"), a leading biopharmaceutical company in the area of antibody-drug conjugates, today announced

  24. Immunomedics Announces FDA Acceptance for Filing of Biologics License Application Resubmission for Sacituzumab Govitecan to Treat Metastatic Triple-Negative Breast Cancer

    Prescription Drug User Fee Act (PDUFA) target action date set for June 2, 2020 MORRIS PLAINS, N.J., Dec. 26, 2019 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (NASDAQ:IMMU) ("Immunomedics" or the "Company"), a leading

  25. Immunomedics Announces Closing of Public Offering of Common Stock

    MORRIS PLAINS, N.J., Dec. 09, 2019 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (NASDAQ:IMMU) ("Immunomedics" or the "Company"), a leading biopharmaceutical company in the area of antibody-drug conjugates (ADC), today

  26. Immunomedics Announces Pricing of Public Offering of Common Stock

    MORRIS PLAINS, N.J., Dec. 04, 2019 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (NASDAQ:IMMU) ("Immunomedics" or the "Company"), a leading biopharmaceutical company in the area of antibody-drug conjugates (ADC), today

  27. Immunomedics Announces Proposed Public Offering of Common Stock

    MORRIS PLAINS, N.J., Dec. 03, 2019 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (NASDAQ:IMMU) ("Immunomedics" or the "Company"), a leading biopharmaceutical company in the area of antibody-drug conjugates (ADC), today

  28. Immunomedics Resubmits Biologics License Application to the FDA for Sacituzumab Govitecan

    MORRIS PLAINS, N.J., Dec. 03, 2019 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (NASDAQ:IMMU) ("Immunomedics" or the "Company"), a leading biopharmaceutical company in the area of antibody-drug conjugates (ADC), today

  29. Immunomedics to Present at Upcoming Healthcare Conferences

    MORRIS PLAINS, N.J., Nov. 13, 2019 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (NASDAQ:IMMU) ("Immunomedics" or the "Company"), a leading biopharmaceutical company in the area of antibody-drug conjugates (ADC), today

  30. Immunomedics Reports Third Quarter 2019 Results and Provides Corporate Update

    TROPHY-U-01 Reached Target Enrollment in Cisplatin-Eligible Cohort of 100 Patients First NSCLC Patient Dosed in Trop-2-Enriched TROPiCS-03 Study BLA Resubmission Targeted for Late November/Early

  31. Immunomedics to Present at the 2019 Cantor Global Healthcare Conference

    MORRIS PLAINS, N.J., Oct. 01, 2019 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (NASDAQ:IMMU) ("Immunomedics" or the "Company"), a leading biopharmaceutical company in the area of antibody-drug conjugates (ADC), today

  32. Immunomedics Provides Corporate Update

    Sacituzumab Govitecan Achieves a 29 Percent Objective Response Rate in 35 Patients With Advanced Urothelial Cancer Who Failed Prior Platinum-Based Regimens and Immunotherapy Future Steps Include Discussing

  33. Immunomedics to Host Investor Event and Webcast on September 28, 2019 During ESMO Congress

    MORRIS PLAINS, N.J., Sept. 12, 2019 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (NASDAQ:IMMU) ("Immunomedics" or the "Company"), a leading biopharmaceutical company in the area of antibody-drug conjugates (ADC), today

  34. Bragar Eagel & Squire is Investigating Certain Officers and Directors of MGT Capital Investments, First American Financial, Immunomedics, and AAC Holdings and Encourages Investors to Contact the Firm

    NEW YORK, Sept. 05, 2019 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire is investigating certain officers and directors of MGT Capital Investments (OTC:MGTI), First American Financial Corporation (NYSE:FAF),

  35. Immunomedics Announces Oral Presentation of Sacituzumab Govitecan in Metastatic Urothelial Cancer at ESMO 2019 Annual Congress

    MORRIS PLAINS, N.J., Sept. 04, 2019 (GLOBE NEWSWIRE) -- Immunomedics, Inc., (NASDAQ:IMMU) ("Immunomedics" or the "Company"), a leading biopharmaceutical company in the area of antibody-drug conjugates (ADC), today

  36. Shareholder Alert: Robbins Arroyo LLP Reminds Investors Immunomedics, Inc. (IMMU) Sued for Misleading Shareholders

    Shareholder rights law firm Robbins Arroyo LLP reminds investors that purchasers of Immunomedics, Inc. (NASDAQGM: IMMU) filed a class action complaint against the company for alleged violations of the Securities

  37. Immunomedics to Participate in Upcoming Healthcare Conferences

    MORRIS PLAINS, N.J., Aug. 28, 2019 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (NASDAQ:IMMU) ("Immunomedics" or the "Company"), a leading biopharmaceutical company in the area of antibody-drug conjugates (ADC), today